<?xml version='1.0' encoding='utf-8'?>
<document id="27572875"><sentence text="Inhibition of pregnane X receptor pathway contributes to the cell growth inhibition and apoptosis of anticancer agents in ovarian cancer cells." /><sentence text="Epithelial ovarian cancer remains the most devastating gynecologic cancer with drug resistance and rapid recurrence" /><sentence text=" Pregnane X receptor (PXR) is a nuclear receptor that affects drug metabolism/efflux and drug-drug interaction through control of multiple drug resistance 1 (MDR1), which implies a major role in multidrug resistance, and other genes" /><sentence text=" We examined whether the inhibition of PXR-mediated pathway using siRNA interference and an antagonist for PXR could influence the paclitaxel and cisplatin cytotoxicity in ovarian cancer cells"><entity charOffset="131-141" id="DDI-PubMed.27572875.s4.e0" text="paclitaxel" /><entity charOffset="146-155" id="DDI-PubMed.27572875.s4.e1" text="cisplatin" /><pair ddi="false" e1="DDI-PubMed.27572875.s4.e0" e2="DDI-PubMed.27572875.s4.e0" /><pair ddi="false" e1="DDI-PubMed.27572875.s4.e0" e2="DDI-PubMed.27572875.s4.e1" /></sentence><sentence text=" PXR agonists, phthalate and pregnenolone had significant positive effects on cytochromeÂ P450 (CYP) 3A4 expression and PXR-mediated transcription through the CYP3A4 promoter, whereas MDR1 expression and PXR-mediated transcription though the MDR1 promoter were significantly increased in the presence of paclitaxel or cisplatin"><entity charOffset="15-24" id="DDI-PubMed.27572875.s5.e0" text="phthalate" /><entity charOffset="29-41" id="DDI-PubMed.27572875.s5.e1" text="pregnenolone" /><entity charOffset="303-313" id="DDI-PubMed.27572875.s5.e2" text="paclitaxel" /><entity charOffset="317-326" id="DDI-PubMed.27572875.s5.e3" text="cisplatin" /><pair ddi="false" e1="DDI-PubMed.27572875.s5.e0" e2="DDI-PubMed.27572875.s5.e0" /><pair ddi="false" e1="DDI-PubMed.27572875.s5.e0" e2="DDI-PubMed.27572875.s5.e1" /><pair ddi="false" e1="DDI-PubMed.27572875.s5.e0" e2="DDI-PubMed.27572875.s5.e2" /><pair ddi="false" e1="DDI-PubMed.27572875.s5.e0" e2="DDI-PubMed.27572875.s5.e3" /><pair ddi="false" e1="DDI-PubMed.27572875.s5.e1" e2="DDI-PubMed.27572875.s5.e1" /><pair ddi="false" e1="DDI-PubMed.27572875.s5.e1" e2="DDI-PubMed.27572875.s5.e2" /><pair ddi="false" e1="DDI-PubMed.27572875.s5.e1" e2="DDI-PubMed.27572875.s5.e3" /><pair ddi="false" e1="DDI-PubMed.27572875.s5.e2" e2="DDI-PubMed.27572875.s5.e2" /><pair ddi="false" e1="DDI-PubMed.27572875.s5.e2" e2="DDI-PubMed.27572875.s5.e3" /></sentence><sentence text=" Downregulation of PXR suppressed the augmented MDR1 expression and PXR-mediated transcription by PXR ligands, and significantly enhanced cell growth inhibition and apoptosis in the presence of paclitaxel or cisplatin"><entity charOffset="194-204" id="DDI-PubMed.27572875.s6.e0" text="paclitaxel" /><entity charOffset="208-217" id="DDI-PubMed.27572875.s6.e1" text="cisplatin" /><pair ddi="false" e1="DDI-PubMed.27572875.s6.e0" e2="DDI-PubMed.27572875.s6.e0" /><pair ddi="false" e1="DDI-PubMed.27572875.s6.e0" e2="DDI-PubMed.27572875.s6.e1" /></sentence><sentence text=" Additionally, ketoconazole, a PXR antagonist, suppressed the augmented MDR1 expression and PXR-mediated transactivation by paclitaxel and cisplatin, and enhanced cell growth inhibition and apoptosis in their presence"><entity charOffset="15-27" id="DDI-PubMed.27572875.s7.e0" text="ketoconazole" /><entity charOffset="124-134" id="DDI-PubMed.27572875.s7.e1" text="paclitaxel" /><entity charOffset="139-148" id="DDI-PubMed.27572875.s7.e2" text="cisplatin" /><pair ddi="false" e1="DDI-PubMed.27572875.s7.e0" e2="DDI-PubMed.27572875.s7.e0" /><pair ddi="false" e1="DDI-PubMed.27572875.s7.e0" e2="DDI-PubMed.27572875.s7.e1" /><pair ddi="false" e1="DDI-PubMed.27572875.s7.e0" e2="DDI-PubMed.27572875.s7.e2" /><pair ddi="false" e1="DDI-PubMed.27572875.s7.e1" e2="DDI-PubMed.27572875.s7.e1" /><pair ddi="false" e1="DDI-PubMed.27572875.s7.e1" e2="DDI-PubMed.27572875.s7.e2" /></sentence><sentence text=" In conclusion, inhibition of PXR-mediated pathways could be a novel means of augmenting sensitivity, or overcoming resistance to anticancer agents for ovarian cancer" /><sentence text=" " /></document>